Abbott India Limited

ABBOTINDIA

INE358A01014

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 02:36:03 2024-04-26 am EDT			5-day change	1st Jan Change
25,978 ^INR	+1.23%		-0.59%	+13.68%

Apr. 12	Abbott India Limited Appoints Murari Ranganathan as Commercial Director	CI
Mar. 19	Abbott India's Managing Director Exits	MT

Abbott India Limited Reports Earnings Results for the First Quarter Ended June 30, 2021

August 06, 2021 at 02:36 am EDT

Abbott India Limited announced earnings results for the first quarter ended June 30, 2021. For the first quarter, the company announced total revenue was INR 12,370.4 million compared to INR 10,919 million a year ago. Net income was INR 1,957.6 million compared to INR 1,803.5 million a year ago. Basic earnings per share from continuing operations was INR 92.12 compared to INR 84.87 a year ago.

Latest news about Abbott India Limited

Abbott India Limited Appoints Murari Ranganathan as Commercial Director	Apr. 12	CI
Abbott India's Managing Director Exits	Mar. 19	MT
Abbott India Limited Announces Resignation of Sandeep Reddy - Commercial Director - Women's Health, Metabolics and International Business, with Effect from June 5, 2024	Mar. 15	CI
Abbott India Names Managing Director	Mar. 13	MT
GSK India arm's Q3 profit falls on government price cap	Feb. 12	RE
Abbott India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 14	CI
Abbott India Managing Director to Step Down in March 2024	Dec. 19	MT
Abbott India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
INDIA STOCKS-Indian shares set for muted opening; Delta Corp in focus after tax notice	23-09-24	RE
Abbott India warns of laxatives shortage in tussle with Goa regulator	23-09-22	RE
Goa state warns Abbott India on antacid license suspension	23-09-14	RE
Abbott India Limited Approves Appointment of Sangeeta Shetty as Company Secretary, Effective September 14, 2023	23-08-09	CI
Abbott India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-09	CI
Abbott India Limited Appoints Ms Richa Tripathi as Associate Director, Effective August 3, 2023	23-07-24	CI
INDIA STOCKS-Indian shares recover from weak start on buying at key levels	23-05-22	RE
Abbott India Limited Approves the Appointment of Sridhar Kadangode as Chief Financial Officer, Effective July 1, 2023	23-05-19	CI
Abbott's India arm posts 9.5% rise in fourth-quarter profit	23-05-19	RE
Abbott India's Net Profit Climbs in Fiscal Q4	23-05-19	MT
Abbott India Limited Approves the Appointment of Mahadeo Karnik as an Additional and Non-Executive Director on the Board, Effective July 1, 2023	23-05-19	CI
Abbott India Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-19	CI
Abbott India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-19	CI
Abbott India Limited Recommends Payment of Final Dividend for the Year Ended March 31, 2023, Payable on or After, August 16, 2023	23-05-19	CI
Abbott India Limited Recommends Special Dividend for the Year Ended March 31, 2023, Payable on or After, August 16, 2023	23-05-19	CI
Pfizer's India unit posts 3% rise in Q4 profit	23-05-15	RE
Abbott India Limited Announces the Resignation of Krupa Anandpara as Company Secretary and Compliance Officer, Effective on June 30, 2023	23-04-07	CI

Chart Abbott India Limited

Duration

Period

More charts

Company Profile

Abbott India Limited is an India-based company that is engaged in the pharmaceuticals business. The Company has a portfolio of offerings in diagnostics, medical devices, nutrition products and branded generic medicines. It provides products and solutions across various therapeutic areas, such as women's health, gastroenterology, central nervous system, metabolic, multi-specialty, and vaccines, among others. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Zolfresh (insomnia), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Creon (pancreatic insufficiency), Cremaffin Plus (Constipation), Pankreoflat (indigestion), Brufen P (fever), Duvadilan (preterm labor), and others. It offers various products under brands, such as Similac, PediaSure, Pedialyte, EleCare, Ensure, Glucerna, and others.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Abbott India Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBOTT INDIA LIMITED	+13.68%	6.55B
NOVO NORDISK A/S	+24.17%	556B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+7.95%	296B
ASTRAZENECA PLC	+13.45%	233B
NOVARTIS AG	+6.04%	201B
ROCHE HOLDING AG	-10.51%	193B
PFIZER, INC.	-12.26%	143B
AMGEN INC.	-6.47%	144B

Other Pharmaceuticals